HIGHLIGHTS
- who: Angelo Mandarino from the (UNIVERSITY) have published the paper: Modifying dolutegravir to PrEPare for long life, in the Journal: (JOURNAL)
SUMMARY
OPEN Modifying dolutegravir to PrEPare for long life Anti-retroviral therapy with drugs like dolutegravir is a powerful tool in both the treatment and prevention of HIV, but is limited by strict adherence to a daily therapeutic regimen. In a recent study, Deodhar, Sillman, and colleagues developed a dolutegravir prodrug that offers long-lasting protection against HIV infection, with the potential to dramatically improve anti-retroviral therapy efficacy. Four decades later . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.